Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

Gen Lin; Zhijie Wang; Qian Chu; Yi Hu; Dingzhi Huang; Jun Wang; Fan Yang; Wenzhao Zhong; Chengzhi Zhou; Bo Zhu; Xinghao Ai; Baoshan Cao; Yabing Cao; Mingqiu Chen; Xiaohui Chen; Tianqing Chu; Jianchun Duan; Yun Fan; Yong Fang; Shuitu Feng; Weineng Feng; Hui Guo; Chengbo Han; Yong He; Shaodong Hong; Jie Hu; Meijuan Huang; Yan Huang; Da Jiang; Kan Jiang; Richeng Jiang; Bo Jin; Shi Jin; Jisheng Li; Min Li; Ziming Li; Chao Li; Jie Lin; Anwen Liu; Si Yang Maggie Liu; Liu Yutao; Zhefeng Liu; Zhe Liu; Zhenhua Liu; Zhentian Liu; Zhigang Liu; Yuping Lu; Tangfeng Lv; Zhiyong Ma; Qian Miao; Min Peng; Xingxiang Pu; Xiu Bao Ren; Jianzhen Shan; Jinlu Shan; Peng Shen; Bo Shen; Meiqi Shi; Yong Song; Zhengbo Song; Chun Xia Su; Jianguo Sun; Panwen Tian; Jinliang Wang; Feng Wang; Huijuan Wang; Jialei Wang; Qian Wang; Wenxian Wang; Yan Wang; Lin Wu; Fang Wu; Yang Xia; Congying Xie; Conghua Xie; Tao Xin; Jianping Xiong; Haipeng Xu; Song Xu; Yiquan Xu; Bin Xu; Chunwei Xu; Xiaolong Yan; Zhenzhou Yang; Wenxiu Yao; Yao Yu; Ye Feng; Zongyang Yu; Yongfeng Yu; Dongsheng Yue; Haibo Zhang; Hong Mei Zhang; Li Zhang; Longfeng Zhang; Qiuyu Zhang; Tongmei Zhang; Bicheng Zhang; Jun Zhao; Mingfang Zhao; Xiaobin Zheng; Qiaofeng Zhong; Jin Zhou; Penghui Zhou; Zhengfei Zhu; Juntao Zou; Zihua Zou

doi:10.1111/1759-7714.15209

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

Gen Lin
, Zhijie Wang
, Qian Chu
, Yi Hu
, Dingzhi Huang
, Jun Wang
, Fan Yang
, Wenzhao Zhong
, Chengzhi Zhou
, Bo Zhu
, Xinghao Ai
, Baoshan Cao
, Yabing Cao
, Mingqiu Chen
, Xiaohui Chen
, Tianqing Chu
, Jianchun Duan
, Yun Fan
, Yong Fang
, Shuitu Feng

Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, Chun Xia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, Hong Mei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou

Fujian Medical University
Chinese Academy of Medical Sciences
Huazhong University of Science and Technology
General Hospital of People's Liberation Army
Tianjin Medical University
Shandong First Medical University & Shandong Academy of Medical Sciences
Peking University
Guangdong Academy of Medical Sciences
The First Affiliated Hospital of Guanzhou Medical University
Chongqing Medical University
Shanghai Jiao Tong University
Kiang Wu Hospital
Zhejiang Cancer Hospital
Sir Run Run Shaw Hospital
Fudan University
First People's Hospital of Foshan
The First Affiliated Hospital of Xi’an Jiaotong University
China Medical University
Sun Yat-Sen University Cancer Center
Sichuan University
Hebei Medical University
Qilu Hospital of Shandong University
Central South University
Kunming Medical College
Nanchang University
Jinan University
Capital Medical University
Jiangxi Cancer Hospital
Southern Medical University
Nanjing University
Zhengzhou University
Renmin Hospital of Wuhan University
Zhejiang University School of Medicine
Jiangsu Institute of Cancer Institute & Hospital
Tongji University
Affiliated Hospital of Nanjing University of Chinese Medicine
The Second Affiliated Hospital of Zhejiang University School of Medicine
the Second Affiliated Hospital of Wenzhou Medical University
Zhongnan Hospital of Wuhan University
The Second Affiliated Hospital of Harbin Medical University
Tangdu Hospital, Fourth Military Medical University
The Second Affiliated Hospital of Chongqing Medical University
University of Electronic Science and Technology of China
The First Affiliated Hospital of Xiamen University
People's Liberation Army of China
Guangdong Provicial Hospital of Chinese Medicine
Xijing Hospital

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

Original language	English
Pages (from-to)	419-426
Number of pages	8
Journal	Thoracic Cancer
Volume	15
Issue number	5
DOIs	https://doi.org/10.1111/1759-7714.15209
State	Published - Feb 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ICI
NSCLC
re-challenge

Access to Document

10.1111/1759-7714.15209

Cite this

@article{97463befe3754084867513dff949568e,

title = "Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer",

abstract = "Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74\% experts agreed to rechallenge; 48.87\% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3\% agreed to rechallenge directly after progression; 88.06\% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.",

keywords = "ICI, NSCLC, re-challenge",

author = "Gen Lin and Zhijie Wang and Qian Chu and Yi Hu and Dingzhi Huang and Jun Wang and Fan Yang and Wenzhao Zhong and Chengzhi Zhou and Bo Zhu and Xinghao Ai and Baoshan Cao and Yabing Cao and Mingqiu Chen and Xiaohui Chen and Tianqing Chu and Jianchun Duan and Yun Fan and Yong Fang and Shuitu Feng and Weineng Feng and Hui Guo and Chengbo Han and Yong He and Shaodong Hong and Jie Hu and Meijuan Huang and Yan Huang and Da Jiang and Kan Jiang and Richeng Jiang and Bo Jin and Shi Jin and Jisheng Li and Min Li and Ziming Li and Chao Li and Jie Lin and Anwen Liu and Liu, \{Si Yang Maggie\} and Liu Yutao and Zhefeng Liu and Zhe Liu and Zhenhua Liu and Zhentian Liu and Zhigang Liu and Yuping Lu and Tangfeng Lv and Zhiyong Ma and Qian Miao and Min Peng and Xingxiang Pu and Ren, \{Xiu Bao\} and Jianzhen Shan and Jinlu Shan and Peng Shen and Bo Shen and Meiqi Shi and Yong Song and Zhengbo Song and Su, \{Chun Xia\} and Jianguo Sun and Panwen Tian and Jinliang Wang and Feng Wang and Huijuan Wang and Jialei Wang and Qian Wang and Wenxian Wang and Yan Wang and Lin Wu and Fang Wu and Yang Xia and Congying Xie and Conghua Xie and Tao Xin and Jianping Xiong and Haipeng Xu and Song Xu and Yiquan Xu and Bin Xu and Chunwei Xu and Xiaolong Yan and Zhenzhou Yang and Wenxiu Yao and Yao Yu and Ye Feng and Zongyang Yu and Yongfeng Yu and Dongsheng Yue and Haibo Zhang and Zhang, \{Hong Mei\} and Li Zhang and Longfeng Zhang and Qiuyu Zhang and Tongmei Zhang and Bicheng Zhang and Jun Zhao and Mingfang Zhao and Xiaobin Zheng and Qiaofeng Zhong and Jin Zhou and Penghui Zhou and Zhengfei Zhu and Juntao Zou and Zihua Zou",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Thoracic Cancer published by John Wiley \& Sons Australia, Ltd.",

year = "2024",

month = feb,

doi = "10.1111/1759-7714.15209",

language = "英语",

volume = "15",

pages = "419--426",

journal = "Thoracic Cancer",

issn = "1759-7706",

publisher = "John Wiley and Sons Inc",

number = "5",

}

Lin, G, Wang, Z, Chu, Q, Hu, Y, Huang, D, Wang, J, Yang, F, Zhong, W, Zhou, C, Zhu, B, Ai, X, Cao, B, Cao, Y, Chen, M, Chen, X, Chu, T, Duan, J, Fan, Y, Fang, Y, Feng, S, Feng, W, Guo, H, Han, C, He, Y, Hong, S, Hu, J, Huang, M, Huang, Y, Jiang, D, Jiang, K, Jiang, R, Jin, B, Jin, S, Li, J, Li, M, Li, Z, Li, C, Lin, J, Liu, A, Liu, SYM, Yutao, L, Liu, Z, Liu, Z, Liu, Z, Liu, Z, Liu, Z, Lu, Y, Lv, T, Ma, Z, Miao, Q, Peng, M, Pu, X, Ren, XB, Shan, J, Shan, J, Shen, P, Shen, B, Shi, M, Song, Y, Song, Z, Su, CX, Sun, J, Tian, P, Wang, J, Wang, F, Wang, H, Wang, J, Wang, Q, Wang, W, Wang, Y, Wu, L, Wu, F, Xia, Y, Xie, C, Xie, C, Xin, T, Xiong, J, Xu, H, Xu, S, Xu, Y, Xu, B, Xu, C, Yan, X, Yang, Z, Yao, W, Yu, Y, Feng, Y, Yu, Z, Yu, Y, Yue, D, Zhang, H, Zhang, HM, Zhang, L, Zhang, L, Zhang, Q, Zhang, T, Zhang, B, Zhao, J, Zhao, M, Zheng, X, Zhong, Q, Zhou, J, Zhou, P, Zhu, Z, Zou, J & Zou, Z 2024, 'Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer', Thoracic Cancer, vol. 15, no. 5, pp. 419-426. https://doi.org/10.1111/1759-7714.15209

TY - JOUR

T1 - Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

AU - Lin, Gen

AU - Wang, Zhijie

AU - Chu, Qian

AU - Hu, Yi

AU - Huang, Dingzhi

AU - Wang, Jun

AU - Yang, Fan

AU - Zhong, Wenzhao

AU - Zhou, Chengzhi

AU - Zhu, Bo

AU - Ai, Xinghao

AU - Cao, Baoshan

AU - Cao, Yabing

AU - Chen, Mingqiu

AU - Chen, Xiaohui

AU - Chu, Tianqing

AU - Duan, Jianchun

AU - Fan, Yun

AU - Fang, Yong

AU - Feng, Shuitu

AU - Feng, Weineng

AU - Guo, Hui

AU - Han, Chengbo

AU - He, Yong

AU - Hong, Shaodong

AU - Hu, Jie

AU - Huang, Meijuan

AU - Huang, Yan

AU - Jiang, Da

AU - Jiang, Kan

AU - Jiang, Richeng

AU - Jin, Bo

AU - Jin, Shi

AU - Li, Jisheng

AU - Li, Min

AU - Li, Ziming

AU - Li, Chao

AU - Lin, Jie

AU - Liu, Anwen

AU - Liu, Si Yang Maggie

AU - Yutao, Liu

AU - Liu, Zhefeng

AU - Liu, Zhe

AU - Liu, Zhenhua

AU - Liu, Zhentian

AU - Liu, Zhigang

AU - Lu, Yuping

AU - Lv, Tangfeng

AU - Ma, Zhiyong

AU - Miao, Qian

AU - Peng, Min

AU - Pu, Xingxiang

AU - Ren, Xiu Bao

AU - Shan, Jianzhen

AU - Shan, Jinlu

AU - Shen, Peng

AU - Shen, Bo

AU - Shi, Meiqi

AU - Song, Yong

AU - Song, Zhengbo

AU - Su, Chun Xia

AU - Sun, Jianguo

AU - Tian, Panwen

AU - Wang, Jinliang

AU - Wang, Feng

AU - Wang, Huijuan

AU - Wang, Jialei

AU - Wang, Qian

AU - Wang, Wenxian

AU - Wang, Yan

AU - Wu, Lin

AU - Wu, Fang

AU - Xia, Yang

AU - Xie, Congying

AU - Xie, Conghua

AU - Xin, Tao

AU - Xiong, Jianping

AU - Xu, Haipeng

AU - Xu, Song

AU - Xu, Yiquan

AU - Xu, Bin

AU - Xu, Chunwei

AU - Yan, Xiaolong

AU - Yang, Zhenzhou

AU - Yao, Wenxiu

AU - Yu, Yao

AU - Feng, Ye

AU - Yu, Zongyang

AU - Yu, Yongfeng

AU - Yue, Dongsheng

AU - Zhang, Haibo

AU - Zhang, Hong Mei

AU - Zhang, Li

AU - Zhang, Longfeng

AU - Zhang, Qiuyu

AU - Zhang, Tongmei

AU - Zhang, Bicheng

AU - Zhao, Jun

AU - Zhao, Mingfang

AU - Zheng, Xiaobin

AU - Zhong, Qiaofeng

AU - Zhou, Jin

AU - Zhou, Penghui

AU - Zhu, Zhengfei

AU - Zou, Juntao

AU - Zou, Zihua

PY - 2024/2

Y1 - 2024/2

N2 - Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

AB - Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

KW - ICI

KW - NSCLC

KW - re-challenge

UR - https://www.scopus.com/pages/publications/85182498111

U2 - 10.1111/1759-7714.15209

DO - 10.1111/1759-7714.15209

M3 - 文章

C2 - 38219795

AN - SCOPUS:85182498111

SN - 1759-7706

VL - 15

SP - 419

EP - 426

JO - Thoracic Cancer

JF - Thoracic Cancer

IS - 5

ER -

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this